Wed, Mar. 25, 9:11 AM
Mon, Mar. 23, 7:58 AM| Comment!
Mon, Mar. 23, 7:08 AM
Wed, Mar. 11, 11:34 AM
Wed, Mar. 11, 9:11 AM
Fri, Mar. 6, 12:45 PM
Fri, Mar. 6, 9:21 AM| Comment!
Fri, Mar. 6, 9:15 AM
Dec. 23, 2014, 4:29 PM
- BioLineRx (NASDAQ:BLRX) grants an exclusive license to Omega Pharma for BL-5010 for the non-surgical removal of benign skin lesions, for over-the-counter (OTC) indications, in the territory of Europe, Australia and selected other countries. BioLineRx will retain the rights in the U.S. and rest of the world.
- Under the terms of the agreement, Omega will be responsible for all development activities required to obtain regulatory approval in the licensed territory for at least two OTC indications. It will also be responsible for manufacturing and commercialization.
- The specific financial terms of the contract are undisclosed.
Dec. 16, 2014, 7:33 AM
- Israel-based BioLineRx (NASDAQ:BLRX) enters into a strategic collaboration with Novartis (NYSE:NVS) to designed to facilitate the development and commercialization drug candidates identified by BioLineRx. The companies will co-develop up to three pre-clinical and early clinical therapeutic product candidates through clinical proof-of-concept. Projects reaching the clinical stage will be eligible for selection by Novartis. If selected, it will pay BioLineRx an option fee of $5M as well as fund 50% of the remaining development costs associated with establishing clinical proof-of-concept. The funding will be in the form of an additional equity investment in BioLineRx.
- As part of the agreement, Novartis has made an initial equity investment in BioLineRx of $10M (5M BLRX ADSs at $2.00 per share) which represents a 12.8% stake.
- BLRX is up 17% premarket on modest volume.
Nov. 10, 2014, 12:17 PM
Nov. 10, 2014, 7:18 AM
Nov. 5, 2014, 8:22 AM
- BioLineRx Ltd.'s (NASDAQ:BLRX) product candidate for the treatment of celiac disease, BL-7010, was found to be safe and well tolerated in a Phase 1/2 clinical trial. The company expects a placebo-controlled efficacy study to commence in 2H 2015.
- BL-7010 is an orally available co-polymer with a high affinity for gliadens, the immunogenic proteins in gluten that cause celiac disease. By sequestering gliadens, BL-7010 masks them from enzymatic degradation and prevents the formation of immunogenic peptides that trigger the immune system.
Oct. 7, 2014, 9:54 AM
- Menlo Park, CA-based Virobay (VBAY) is set for its IPO of 3.8M shares at $12 - 14.
- The clinical stage biopharmaceutical firm develops drugs based on its cysteine cathepsin platform. Cysteine cathepsins are important enzymes in the biology of many diseases. The company believes that inhibiting these enzymes produces safer, more effective therapies. It currently focuses its efforts on inhibitors of cathepsins S and B.
- Its lead product candidates are cathepsin S inhibitors: VBY-036 for neuropathic pain and Crohn's disease and VBY-891 for psoriasis. Phase 2 development for all three indications should commence in 1H 2015 which means that meaningful product revenues are far in the distance.
- In 2013, the company generated $9.9M in collaboration revenue. Its operating loss was ($2.3M). In 1H 2015, collaboration revenue dropped to $1.1M and the loss from operations increased to ($3.6M).
- Crohn's disease-related tickers: (ABBV -1.6%)(MRK -1.2%)(RDHL +0.4%)(VBLX)(OTCPK:TKPHF)(OTCPK:TKPYY)(CNDO +1.1%)(OTCQB:SNGX)(PSTI +2.3%)
- Neuropathic pain-related tickers: (DARA -4.4%)(AVNR -3.4%)(ZLCS +0.9%)(IPCI -2%)(BLRX -1.9%)(MNOV +0.6%)(PFE -0.3%)(OTCPK:NGSX)
- Psoriasis-related tickers: (DERM -0.5%)(NVS -2.5%)(CELG -1.4%)(LLY -1.3%)(CANF -2.3%)(IDRA -1.4%)(JNJ -0.8%)(XNPT +0.5%)(HSP -0.2%)
Aug. 21, 2014, 7:47 AM
- The USPTO issues a Notice of Allowance to BioLineRx (NASDAQ:BLRX) covering the use of its polymer, BL-7010, for the prevention or decreasing of gluten's deleterious side effects on the gastrointestinal mucosa. The patent, when issued, will be in effect until 2026.
- BL-7010 is a non-absorbable orally available polymer intended for the treatment of celiac disease. It has a high affinity for gliadins, the immunogenic proteins in gluten that cause celiac disease. BL-7010 masks gliadins from enzymatic degradation which prevents the formation of immunogenic peptides that trigger the immune response. The immune response to gluten is thereby significantly reduced. BL-7010 is excreted via the bowel and not absorbed into the blood stream.
Aug. 6, 2014, 11:08 AM
BLRX vs. ETF Alternatives
Other News & PR